Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a […]